The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...
Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...
Seamless Therapeutics inks research collaboration with Lilly to develop programmable recombinase-based therapeutics for hearing loss: Dresden, Germany Friday, January 30, 2026, 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results